TY - JOUR
T1 - Additive effects of booster mRNA vaccination and SARSCoV-2 Omicron infection on T cell immunity across immunocompromised states
AU - Müller, Thomas R.
AU - Sekine, Takuya
AU - Trubach, Darya
AU - Niessl, Julia
AU - Chen, Puran
AU - Bergman, Peter
AU - Blennow, Ola
AU - Hansson, Lotta
AU - Mielke, Stephan
AU - Nowak, Piotr
AU - Vesterbacka, Jan
AU - Akber, Mira
AU - Olofsson, Anna
AU - Hernandez, Susana Patricia Amaya
AU - Gao, Yu
AU - Cai, Curtis
AU - Söderdahl, Gunnar
AU - Smith, C. I.Edvard
AU - Österborg, Anders
AU - Loré, Karin
AU - Chen, Margaret Sällberg
AU - Ljungman, Per
AU - Ljunggren, Hans Gustaf
AU - Karlsson, Annika C.
AU - Saini, Sunil Kumar
AU - Aleman, Soo
AU - Buggert, Marcus
N1 - Publisher Copyright:
Copyright © 2023 Th Authors, some rights reserved.
PY - 2023
Y1 - 2023
N2 - Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in individuals with various immunodeficiencies. Given the increased antibody evasion properties of emerging SARS-CoV-2 subvariants, it is necessary to assess whether other components of adaptive immunity generate resilient and protective responses against infection. We assessed T cell responses in 279 individuals, covering five different immunodeficiencies and healthy controls, before and after booster mRNA vaccination, as well as after Omicron infection in a subset of patients. We observed robust and persistent Omicron-reactive T cell responses that increased markedly upon booster vaccination and correlated directly with antibody titers across all patient groups. Poor vaccination responsiveness in immunocompromised or elderly individuals was effectively counteracted by the administration of additional vaccine doses. Functionally, Omicron-reactive T cell responses exhibited a pronounced cytotoxic profile and signs of longevity, characterized by CD45RA+ effector memory subpopulations with stem cell–like properties and increased proliferative capacity. Regardless of underlying immunodeficiency, booster-vaccinated and Omicron-infected individuals appeared protected against severe disease and exhibited enhanced and diversified T cell responses against conserved and Omicron-specific epitopes. Our findings indicate that T cells retain the ability to generate highly functional responses against newly emerging variants, even after repeated antigen exposure and a robust immunological imprint from ancestral SARS-CoV-2 mRNA vaccination.
AB - Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in individuals with various immunodeficiencies. Given the increased antibody evasion properties of emerging SARS-CoV-2 subvariants, it is necessary to assess whether other components of adaptive immunity generate resilient and protective responses against infection. We assessed T cell responses in 279 individuals, covering five different immunodeficiencies and healthy controls, before and after booster mRNA vaccination, as well as after Omicron infection in a subset of patients. We observed robust and persistent Omicron-reactive T cell responses that increased markedly upon booster vaccination and correlated directly with antibody titers across all patient groups. Poor vaccination responsiveness in immunocompromised or elderly individuals was effectively counteracted by the administration of additional vaccine doses. Functionally, Omicron-reactive T cell responses exhibited a pronounced cytotoxic profile and signs of longevity, characterized by CD45RA+ effector memory subpopulations with stem cell–like properties and increased proliferative capacity. Regardless of underlying immunodeficiency, booster-vaccinated and Omicron-infected individuals appeared protected against severe disease and exhibited enhanced and diversified T cell responses against conserved and Omicron-specific epitopes. Our findings indicate that T cells retain the ability to generate highly functional responses against newly emerging variants, even after repeated antigen exposure and a robust immunological imprint from ancestral SARS-CoV-2 mRNA vaccination.
U2 - 10.1126/scitranslmed.adg9452
DO - 10.1126/scitranslmed.adg9452
M3 - Journal article
C2 - 37437015
AN - SCOPUS:85164542192
SN - 1946-6234
VL - 15
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 704
M1 - eadg9452
ER -